Fundraising Fox
/Companies
Sign in

Anaveon

Basel, CH · 5 known investors

Find your way into Anaveon

Each arrow is one introduction. Sign up to fill in the first one.

29 people can intro you to Thaminda

Ask Dominic Schmidt to introduce you to Thaminda Ramanayake

You →Dominic · together at Anaveon →Thaminda

Sign up to find every way you can get introduced to Anaveon

  • Your email: who you already know at Anaveon, and who your contacts know
  • 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Anaveon team
  • Your LinkedIn: the connections who can make the intro for you

We rank every route by how warm it is, so you raise on warm intros instead of cold emails.

Sign up with GoogleAlready have an account? Log in

Anaveon develops engineered antibodies targeting immune system regulatory nodes to treat autoimmune diseases by selectively eliminating or reprogramming pathogenic immune cells. The company is a late-stage preclinical biotech focused on precision biologics for immune-mediated disease.

Biotech

Founders & leadership

TThaminda
ThamindaChief Business OfficerThaminda is Chief Business Officer at Anaveon, a biotech company developing engineered antibodies for autoimmune diseases. He has published research in life sciences and experience in complex business negotiations and team building.
LPLaetitia Pouzol
Laetitia PouzolChief Scientific Officer
JM
Jill Marie Jene
TM
Tom Mathers

Investors · 5

Pfizer Venture Investmentslisted by Pfizer Venture Investments$5M – $20M

How we know: the VCSheet dataset · Not right? Tell us

Pontifax Venture Capitallisted by Pontifax Venture CapitalHerzeliya

How we know: Pontifax Venture Capital's portfolio page · the VCSheet dataset · Not right? Tell us

Synconalisted by SynconaLondon

How we know: Syncona's portfolio page · funding news · labiotech.eu · Not right? Tell us

ForbionreportedNaarden

How we know: a partner's Signal profile · Not right? Tell us

Funding

SEC filings, press & company announcements

Source: company announcements and press reports — follow each round's link for the claim.

Related companies · 3

Abeona TherapeuticsAbeona Therapeutics is a commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases with high unmet need, including its approved product ZEVASKYN and its lead PSMA-targeted T cell therapy ABO-701 for advanced prostate cancer. It uses ex vivo gene therapy, viral vector, and synthetic immune receptor T cell (SIR-T) technologies to serve patients with genetic diseases and solid tumors.
Averna TherapeuticsAverna Therapeutics is a biotechnology company developing therapeutics. The page is a team bio profiling its CEO and board member.
Anavex Life SciencesAnavex Life Sciences is a clinical-stage biopharmaceutical company developing oral therapeutics for central nervous system disorders, including Alzheimer's disease, Rett syndrome, and Fragile X syndrome. Its lead compound is ANAVEX 2-73 (blarcamesine), targeting early Alzheimer's and neurodevelopmental rare diseases.

Companies working in the same space as Anaveon.

In the news

Anaveon to raise CHF 110 million in oversubscribed Series B financingglobenewswire.com · Dec 2021

Frequently asked questions

What does Anaveon do?
Anaveon develops engineered antibodies targeting immune system regulatory nodes to treat autoimmune diseases by selectively eliminating or reprogramming pathogenic immune cells. The company is a late-stage preclinical biotech focused on precision biologics for immune-mediated disease.
Who are Anaveon's investors?
Anaveon's investors include Novartis Venture Fund, Pfizer Venture Investments, Pontifax Venture Capital, Syncona, Forbion.
Where is Anaveon headquartered?
Anaveon is headquartered in Basel, CH.